Assessment of the Automated Bone Scan Index as a Biomarker of mCRPC Survival in Metastatic Prostate Cancer
This secondary analysis of a randomized clinical trial assesses the automated Bone Scan Index as an independent prognostic determinant of overall survival in men with metastatic castration-resistant prostate cancer.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου